|
| Friday, November 27, 2020 |
|
|
Jacobson Pharma Announces FY2021 Interim Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced the interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2020 (the "reporting period"). more info >> |
|
| Wednesday, September 23, 2020 |
|
|
Jacobson Pharma Submits Form A1 to Spin-off Its Branded Healthcare Business |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or "the Group"; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare products in Hong Kong more info >> |
|
| Thursday, August 27, 2020 |
|
|
Jacobson Pharma Collaborates with Fosun Pharma Group to Supply Potentially 10 Million Doses of BioNTech SE's COVID-19 Vaccine Candidate in Hong Kong and Macau |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or "the Group"; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare products in Hong Kong, today announced the signing of a letter of intent ("Letter of Intent") with Fosun Industrial Co. Ltd. more info >> |
|
| Tuesday, June 30, 2020 |
|
|
Jacobson Pharma Announces FY2020 Annual Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2020 (the "FY2020" or the "Reporting Period"). more info >> |
|
| Wednesday, February 5, 2020 |
|
|
Jacobson Pharma Launches First Influenza/RSV Home Diagnostic Kit in Hong Kong and Macau |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in research, development, production, marketing and sale of generic drugs and branded healthcare products more info >> |
|
| Tuesday, November 26, 2019 |
|
|
Jacobson Pharma Announces FY2020 Interim Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its unaudited interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2019 (the "reporting period"). more info >> |
|
| Tuesday, November 12, 2019 |
|
|
Jacobson Pharma Launches Smartfish Health Nutrition Products from Norway in Greater China and Asia Pacific Region |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaging in research, development, production, marketing and sale of generic drugs and proprietary medicines more info >> |
|
| Tuesday, November 5, 2019 |
|
|
Jacobson Pharma Adds Excilor to Its Portfolio to Develop China Market with Vemedia (The Netherlands) |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in research, development, production, marketing and sale of generic drugs and proprietary medicines more info >> |
|
| Thursday, October 31, 2019 |
|
|
Jacobson Pharma Forms Joint Venture with Kin Fung Weisen-U |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of generic drugs and proprietary medicines more info >> |
|
| Tuesday, June 25, 2019 |
|
|
Jacobson Pharma Announces FY2019 Annual Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2019 (the "FY2019"). more info >> |
|
|
|
